Form 4: Precigen Director James S. Turley Reports Acquisition of Common Stock and Restricted Stock Units

Director James S. Turley reports acquisition of Precigen common stock and restricted stock units (RSUs) on March 14, 2024.

Summary

• On March 14, 2024, James S. Turley, a director of Precigen, Inc., acquired 43,706 shares of common stock at a price of $1.43 per share.
• These shares were issued in lieu of an annual retainer of $62,500.
• Turley also acquired 87,412 restricted stock units (RSUs), each representing a contingent right to receive one share of Precigen common stock, which vest in full on March 14, 2025.
• Additionally, Turley acquired an option to purchase 101,626 shares of common stock at an exercise price of $1.43, expiring on March 14, 2034.
• Following these transactions, Turley directly owns 472,441 shares of Precigen common stock and 87,412 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The acquisition of shares and RSUs by a director could be seen as a positive sign, but it's not necessarily indicative of a major shift in the company's prospects.

Positives

• The acquisition of shares and RSUs by a director signals confidence in the company's future prospects.
• The issuance of shares in lieu of cash retainer preserves cash for the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in beneficial ownership by a director of Precigen.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.
• The issuance of shares in lieu of cash compensation could be viewed positively by creditors as it preserves cash.

Key Dates